comScore
Active Stocks
Thu Sep 28 2023 09:21:33
  1. Mahindra & Mahindra share price
  2. 1,590.2 0%
  1. Tata Steel share price
  2. 128.9 0.59%
  1. NTPC share price
  2. 240 0.27%
  1. Power Grid Corporation Of India share price
  2. 199.35 0.03%
  1. ICICI Bank share price
  2. 943.4 0.03%
Business News/ News / India/  Biological E seeks EUA for its Corbevax vaccine for 12-18 yrs age group
Back

Biological E seeks EUA for its Corbevax vaccine for 12-18 yrs age group

The DCGI has already approved Corbevax, which is India's first indigenously developed RBD protein sub-unit vaccine against COVID-19, for restricted use in emergency situation among adults on December 28

In this file photo a syringe is filled with a dose of the Pfizer Covid-19 vaccine. (AFP)Premium
In this file photo a syringe is filled with a dose of the Pfizer Covid-19 vaccine. (AFP)

Biological E has sought emergency use authorisation from India's drug regulator for its COVID-19 vaccine Corbevax for the 12 to 18 years age group, official sources said on Sunday.

The Drugs Controller General Of India (DCGI) has already approved Corbevax, which is India's first indigenously developed RBD protein sub-unit vaccine against COVID-19, for restricted use in emergency situation among adults on December 28.

In an application sent to DCGI on February 9, Srinivas Kosaraju, head of Quality and Regulatory Affairs of Biological E Limited, said the firm had received approval for conducting phase 2/3 clinical study of Corbevax among children and adolescents aged 5-18 years in September.

"Based on the no-objection certificate, Biological E has initiated the clinical study in October 2021 and has evaluated the available safety and immunogenicity results of the ongoing phase 2/3 study, which indicated that the vaccine is safe and immunogenic.

"The proposed application is for obtaining permission for restricted use in an emergency situation in adolescents aged 12 to less than 18 years based on interim results (of the ongoing phase 2/3 clinical study) considering the current pandemic and widespread of COVID-19 vaccine in India," Kosaraju said in the application.

The Corbevax vaccine is administered through intramuscular route with two doses scheduled 28 days apart and is stored at 2 to 8 degrees Celsius temperatures and presented as 0.5 ml (single dose) and 5 ml (10 doses) vial pack.

According to the Health Ministry, the company has conducted phase 1/2, 2/3 clinical trials of its COVID-19 vaccine in the country. Further, it has conducted a phase 3 active comparator clinical trial to evaluate superiority against Covishield vaccine, it said.

"Exciting news! Mint is now on WhatsApp Channels 🚀 Subscribe today by clicking the link and stay updated with the latest financial insights!" Click here!

This story has been published from a wire agency feed without modifications to the text.

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Updated: 13 Feb 2022, 03:43 PM IST
Next Story
Recommended For You
Switch to the Mint app for fast and personalized news - Get App